Emerging research illustrates that incretin hormones —GLP-1 and GIP—not only regulate glucose metabolism but also exert direct cardioprotective and renoprotective effects in type 2 diabetes. By orchestrating postprandial vasodilation, increased nutrient uptake, and improved myocardial glucose use, incretins support tissue perfusion and limit cardiac workload, especially during metabolic stress. These hormones also exhibit anti-inflammatory and antioxidant properties, reducing endothelial dysfunction and arterial stiffness and curtailing atherosclerosis risk.
Clinical trials with GLP-1 receptor agonists and dual incretin therapies have demonstrated meaningful reductions in cardiovascular and renal events, highlighting the integral role of these therapies in modern diabetes management. To learn more Click Here ##Reference## Drucker DJ, et al. Incretins and the cardiovascular system:…
